This study was to evaluate the effectiveness and tolerability ofbupropion extended release (XR) in the treatment of patientswith depressive disorder defined with the criteria of DSM-IV formajor depressive disorder (MDD), dysthymia and depressivedisorder NOS for 3 months in a naturalistic treatment settings.The data of 774 participants were analyzed. The primary outcomewas 7-item Hamilton Depression Rating Scale (HAM-D 7) and thesecondary outcome measures were Clinical Global ImpressionScale-Severity (CGI-S) and-Improvement (CGI-I), and SheehanDisability Scale (SDS), which were assessed in the baseline(visit1) and one months (visit 2) and 3 months (visit 3) aftertreatments. The adverse events were systematically collected byTreatment Emergent Adverse Events (TEAEs) and patients’subjective report. The total scores of HAMD-7 significantlydecreased from the baseline (13.1) to the endpoint (5.9) byapproximately 55% after 3 months treatment with bupropion XR.Fifty nine percent of patients felt very much improved or muchimproved at the endpoint after treatment of bupripion XR, while74% of patients showed more than moderate severity measured byCGI-s at the baseline. The total scores of SDS also significantlydecreased at the end of treatment. After treatment, 17% of patientsfelt any of adverse events, in which dry mouth and headache werethe most common side effects and most of the side effects werejudged as mild intensity. Notably weight gain and sexualdysfunction were minimal. At the end of treatment, 75.7% ofpatients were still on bupropion XR and the mean dose ofbupropion XR was 243 mg/d during the study.

Keywords: Depressive disorders; Bupropion XR; Effectiveness;Tolerability

doi:10.1016/j.jad.2010.02.068

[P2.1.04]

Quetiapine XR adjunctive treatment in partially responsivegeneralized anxiety disorder (GAD): An open label study

A. Gabriel

University Of Calgary, Canada

Objective: Adjunctive treatment of Quetiapine XR to otherantidepressants in the treatment of partially responsive, poorlyfunctioning patients with generalized anxiety disorder was assessed.

Method: Sixteen consenting patients with confirmed DSM-IV-Rdiagnosis of generalized disorder were identified as treatmentresistant. All patients failed at least two 8-week treatment trialswith SSRI antidepressant. All were treated with Quetiapine XR as anadjunct to SSRI antidepressants for at least 12 weeks. The primaryefficacy measure was the Clinical Global Impression (CGI-S). Otherscales included; the Hamilton Anxiety Scale (HAM-A) scale, SheehanDisability Scale, and the Abnormal Involuntary Movement Scale(AIMS). Baseline measures prior to adding Quetiapine XR werecompared to those at 4, 8 and 12 weekswith the adjunctive treatment.

Results: Fifteen patients completed the trial. There was sig-nificant rapid resolution of the anxiety symptoms in all effective-ness measures, including the symptoms of anxiety as shown bychanges from baseline in HAM-A, and CGI at four weeks, which wasmaintained to week twelve. Impairments in work, Social, and homeresponsibilities, were also reduced significantly, and there was nosignificant changes in weight at 12 weeks. Patients tolerated theadjunctive treatment well.

Conclusion: Quetiapine XR could be used effectively as adjunctivetreatment with SSRIs in patients suffering from generalized anxiety.

Keywords: Generalized anxiety; Refractory; Quetiapine XR; Treatment

doi:10.1016/j.jad.2010.02.069

[P2.1.05]

Changes in anxiety symptoms of ADHD adult patients withco-morbid refractory generalized anxiety disorder treated withmixed amphetamine salts (ADDERALL XR): An open label study

A. Gabriel

University of Calgary, Canada

Objectives: to examine the effectiveness of the mixed amphe-tamine salt adderall XR, in the treatment of adult Attention DeficitHyperactivity Disorder (ADHD), with comorbid partially responsivegeneralized anxiety (GA).

Method: consenting adult patients (n=32) with confirmeddiagnosis of GA and comorbid ADHD participated in this open labelstudy. All patients had significant comorbid anxiety symptoms(HAM-A >7), and failed to respond to 8 week trials of serotoninreuptake inhibitors (SSRIs) or Serotonin Norepinephrin reuptakeinhibitors (SNRIs). All patients were treated with the mixedamphetamine salt adderall XR, as adjunctive to SSRIs or SNRIsand were followed for at least 12 weeks. The primary effective-ness measure was the Clinical Global Impression severity subscale(CGI-S). Other scales included the Hamilton anxiety scale (HAM-A),the adult ADHD self report scale (ASRS-v1.1) symptom checklist, andSheehan's disability scale. Baseline measures prior to the treatmentwith adderall XR, were compared to those at 4, 8, and at 12 weeks oftreatment.

Results: There was significant resolution of symptoms of alleffectiveness measures, including symptoms of anxiety, as shownby changes from baseline in HAM-A, ASRS-v1.1, and CGI at 8 weeks.Also there was significant reduction in the disability score at12 weeks. Patients tolerated the adjunctive treatment and therewere no significant cardiovascular changes at 12 weeks.

Conclusion: Mixed amphetamine salts adderall XR, can be usedin adult patients with ADHD, and co-morbid anxiety symptoms.Larger controlled studies are needed to examine the effectivenessof mixed amphetamine salts in patients with co-morbid anxietysymptoms.

Keywords: Genaralized Anxiety; Comorbiditties; Adult ADHD; Mixedamphetamine Salts

doi:10.1016/j.jad.2010.02.070

[P2.1.06]

Effect of augmented atypical antipsychotics on weight change inpatients with major depressive disorder in a naturalistic setting

H.J. Seo⁎, Y.E. Jung, Y.S. Woo, T.Y. Jun, J.H. Chae, W.M. Bahk

The Catholic University of Korea, Korea

Abstract/Journal of Affective Disorders 122 (2010) S42–S72S58